White Paper
Launch Excellence IX
Embracing change and unlocking efficiency
Jun 30, 2025
Download

In the next 5 years, Excellent launch matters more than ever, because over $200 billion in revenue is at risk from loss of exclusivity by 2030, and pharmaceutical companies must deliver an unprecedented number of launches, with consistently strong performance, to fill that gap and sustain growth.

Looking ahead to 2030, the path to Excellent launch looks different. Some launch fundamentals remain, but there are new types of launch, new critical investments for launch and new rules impacting global launch performance.

Find out the secrets to unlock efficiency, embrace change and thrive in a fast-paced and volatile environment.

Stay ahead with the EMEA Thought Leadership insights: your source for industry-leading expertise and analysis

Related solutions

Contact Us